Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios’ Katherine Davis reports. The new market for obesity drugs has reshaped dealmaking in biopharma, as big companies look to replace expiring patents and buy into the fast-growing business, the author notes.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $105 from $65 at JPMorgan
- Structure Therapeutics price target raised to $140 from $90 at Guggenheim
- Structure Therapeutics moved to Buy rating at Goldman Sachs
- Novo Nordisk’s renewed M&A appetite sends obesity-drug names higher
- Novo Nordisk says back on the hunt for obesity deals, Bloomberg reports